A pragmatic guide to choosing biologic therapies in severe asthma

Joanne E. Kavanagh, Andrew P. Hearn, David J. Jackson

Source: Breathe, 17 (4) 210144; 10.1183/20734735.0144-2021
Journal Issue: December

Congress or journal article abstractFull text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Joanne E. Kavanagh, Andrew P. Hearn, David J. Jackson. A pragmatic guide to choosing biologic therapies in severe asthma. Breathe, 17 (4) 210144; 10.1183/20734735.0144-2021

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.

Related content which might interest you:
Recommended new therapies for severe asthma and the future
Source: International Congress 2014 – PG05 Severe asthma – highlights from the ERS/ATS workshop
Year: 2014

Recommendations of new therapies for severe asthma and the future
Source: Annual Congress 2013 –ERS/ATS Task Force report on severe asthma
Year: 2013

Who should receive which biologic and why? Current and future approaches in severe asthma patients
Source: Virtual Congress 2021 – Linking scientific mechanisms to recent clinical therapeutic advances in airway disease: why, who, when and what?
Year: 2021

A digital therapy for proactively managing exacerbations and delivering therapeutic benefit to patients with moderate to severe asthma
Source: International Congress 2019 – Clinical approach to asthma management
Year: 2019

A new GINA resource in 2018: a practical guide for assessing and managing difficult-to-treat and severe asthma
Source: International Congress 2018 – GINA 2018 and beyond: shaping the future of asthma management
Year: 2018

COVID-19 conundrum: clinical phenotyping based on pathophysiology as a promising approach to guide therapy in a novel illness
Source: Eur Respir J, 56 (2) 2002135; 10.1183/13993003.02135-2020
Year: 2020

Emerging biologic approaches for the treatment of difficult to control asthma
Source: International Congress 2017 – Pathophysiology and emerging therapies for severe asthma
Year: 2017

Can we use a biomarker to guide antibiotic treatment in severe COPD exacerbations?
Source: Breathe, 15 (4) 353; 10.1183/20734735.0257-2019
Year: 2019

New and future developments of therapy for asthma in children
Source: Eur Respir Mon 2012; 56: 224-234
Year: 2012

Identifying patients with severe asthma that will be benefit from biological therapy
Source: Virtual Congress 2020 – Rethinking asthma
Year: 2020

Do we need new therapies for noneosinophilic asthma?
Source: Annual Congress 2004 - Noneosinophilic asthma
Year: 2004

Revising our approach to conducting therapeutic clinical research in COPD
Source: Eur Respir J, 51 (2) 1702712; 10.1183/13993003.02712-2017
Year: 2018

Measuring airway hyperresponsiveness: does it add to routine measures of clinical efficacy in guiding asthma therapy?
Source: Eur Respir J 2006; 28: Suppl. 50, 319s
Year: 2006

Efficient and practical management for checking inhalation technique and discussing medication adherence before treatment step-up in uncontrolled asthma
Source: International Congress 2018 – Asthma: clinical screening tools
Year: 2018

From guidelines to personalized treatment of children with asthma
Source: Virtual Congress 2020 – Which paediatric asthma guidelines are the most appropriate for children and adolescents?
Year: 2020

Pharmacological strategies for self-management of asthma exacerbations
Source: Eur Respir J 2006; 28: 182-199
Year: 2006

Use of relievers in patients with severe asthma on biologic therapy –a multidisciplinary approach
Source: Virtual Congress 2020 – Challenges and updates in nursing care around the world
Year: 2020

Comparative efficacy of the therapy strategies for the asthma control maintenance in real clinical practice
Source: Annual Congress 2011 - Asthma: control and treatment
Year: 2011

Is poor asthma self-management due to failure to recognise symptoms or failure to act? Novel insights from mining large-scale clinical observational study
Source: International Congress 2019 – M-health/e-health II
Year: 2019